COVID-19 Vaccines and Adverse Effects of SARS-CoV-2 in Recovered Patients of COVID-19: An In-depth Review DOI Creative Commons

B N Raghavendra,

Sudhakar Kancharla,

Prachetha Kolli

et al.

Journal of Pure and Applied Microbiology, Journal Year: 2024, Volume and Issue: 18(3), P. 1424 - 1437

Published: Aug. 29, 2024

Severe Acute Respiratory Syndrome (SARS-CoV-2) causes the coronavirus disease (COVID-19), which is characterised by severe respiratory syndrome and other complications. It a serious threat to global public health if proper vaccination not followed. The efficient COVID-19 management requires along with precautionary measures. Public transmission of seems have decreased immune response viral infections has improved vaccination. present review discusses in detail about current situation COVID-19, based on latest reports approved vaccine types their efficacy, status, various SARS-CoV-2 variants. This also includes insights into post-COVID complications recovered patients. Besides, some ill-effects drugs inducing diseases patients, are discussed this article. study will help researchers prepare strategies for further research production prevent occurrence future.

Language: Английский

Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines DOI
Congrui Zhu,

Shengmei Pang,

Jiaqi Liu

et al.

Drugs, Journal Year: 2024, Volume and Issue: 84(4), P. 403 - 423

Published: April 1, 2024

Language: Английский

Citations

10
Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control DOI Creative Commons
Shen Wang, Wujian Li,

Zhenshan Wang

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: Sept. 11, 2024

Language: Английский

Citations

8
A Review of Protein-Based COVID-19 Vaccines: From Monovalent to Multivalent Formulations DOI Creative Commons
Qian Gui,

Cuige Gao,

Miaomiao Zhang

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(6), P. 579 - 579

Published: May 25, 2024

The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulting in COVID-19 pandemic, has profoundly impacted global healthcare systems and trajectory economic advancement. As nations grapple with far-reaching consequences this unprecedented health crisis, administration vaccines proven to be a pivotal strategy managing crisis. Protein-based have garnered significant attention owing their commendable safety profile precise immune targeting advantages. Nonetheless, unpredictable mutations widespread transmission SARS-CoV-2 posed challenges for vaccine developers governments worldwide. Monovalent multivalent represent two strategies development, ongoing controversy surrounding efficacy. This review concentrates on development protein-based vaccines, specifically addressing transition from monovalent formulations, synthesizes data manufacturers, antigen composition, clinical study findings, other features that shape distinct profiles overall effectiveness. Our hypothesis is could offer enhanced capability broad-spectrum protection.

Language: Английский

Citations

4
Safety and Immunogenicity of the Tetravalent Recombinant COVID-19 Protein Vaccine SCTV01E in Children and Adolescents Aged 3 to 17 Years: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial DOI Creative Commons

Fengcai Zhu,

Ting Huang, Pengfei Jin

et al.

Vaccines, Journal Year: 2025, Volume and Issue: 13(1), P. 43 - 43

Published: Jan. 7, 2025

Background: SCTV01E is a tetravalent recombinant COVID-19 vaccine authorized for emergency use in China adults 18 years and older but not those under 18. Objective: This Phase 2 trial assessed the safety immunogenicity of healthy children adolescents aged 3 to 17 years, establish immunobridging with that observed from efficacy pivotal (NCT05308576). Methods: Participants were randomly assigned receive either 30 µg or placebo. Primary endpoints focused on geometric mean titer (GMT) seroresponse rate (SRR) neutralizing antibodies (nAb) against Omicron BA.5. Results: In total, 268 participants (214 vs. 54 placebo) included analysis, 241 (191 50) analysis. Overall, 127 (59.3%) receiving 9 (16.7%) placebo reported adverse events (AEs), most which Grade 1 2. No serious (SAEs) special interest (AESIs) reported. bridging data 95 youths compared 188 adults; ratio (GMR) titers was 8.78 (95% CI: 6.05-12.74, p < 0.001), lower bound 95% CI exceeding 0.67. The difference SRR 6.34% 0.93-11.22%) (p = 0.029), 95%CI >-5%, indicating superiority. Conclusions: found be safe well tolerated adolescents, generating robust immune response supports its potential younger populations.

Language: Английский

Citations

0
A randomized phase I trial of intranasal SARS-CoV-2 vaccine dNS1-RBD in children aged 3–17 years DOI Creative Commons

Kai Chu,

Jiali Quan,

Xiaohui Liu

et al.

npj Vaccines, Journal Year: 2025, Volume and Issue: 10(1)

Published: March 17, 2025

The intranasal SARS-CoV-2 vaccine dNS1-RBD (Pneucolin®), based on a live-attenuated influenza virus vector, has obtained Emergency Use Authorization in China for individuals aged 18 years and older. Here, we conducted single-center, double-blind, placebo-controlled, age de-escalation phase 1 clinical trial to evaluate the safety of children 3–17 (ChiCTR2300068044). Sixty-three participants received 2 doses or placebo at days 0 14. Safety assessments included adverse events/reactions within 30 serious events (SAEs) over 12 months. Blood nasal secretion samples were collected further monitor blood indices viral shedding. group showed similar reaction rates (39.0% vs 36.4%), with no SAEs related vaccination. Data suggested that is well-tolerated years, warrants studies its safety, immunogenicity efficacy this population.

Language: Английский

Citations

0
Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines DOI Creative Commons
Anthony M. Marchese, Raj Kalkeri,

Muruga Vadivale

et al.

Expert Review of Vaccines, Journal Year: 2023, Volume and Issue: 22(1), P. 620 - 628

Published: June 30, 2023

Introduction Approximately half of the 13.4 billion COVID-19 vaccine doses administered globally were inactivated or viral vector platforms. The harmonization and optimization regimens has become a key focus policy makers healthcare providers presents an opportunity to reassess continued use pandemic-era vaccines.Areas covered Immunological evidence from studies various homologous heterologous been rapidly published, however interpretation these data are complicated by many types highly variable participant exposure vaccination histories. Recent demonstrate that after primary series (i.e. BBV152, BBIBP-CorV), (ChAdOx1 nCov-2019) vaccines, boost with protein-based NVX-CoV2373 elicits more potent ancestral strain omicron-specific antibody responses compared boosts.Expert opinion While mRNA vaccines likely yield similar performance booster doses, later offers notable advantages countries high uptake in terms transportation storage logistics can potentially appeal hesitant individuals. Moving forward, vaccine-mediated protection recipients may be optimized such as NVX-CoV2373.

Language: Английский

Citations

5
Landscape of T cell epitopes displays hot mutations of SARS‐CoV‐2 variant spikes evading cellular immunity DOI
Mengze Gan, Jinge Cao, Yandi Zhang

et al.

Journal of Medical Virology, Journal Year: 2024, Volume and Issue: 96(2)

Published: Feb. 1, 2024

Abstract The continuous evolution of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has been accompanied by the emergence viral mutations that pose a great challenge to existing vaccine strategies. It is not fully understood with regard role on SARS‐CoV‐2 spike protein from emerging variants in T cell immunity. In current study, recombinant eukaryotic plasmids were constructed as DNA vaccines express multiple strains. These used immunize BALB/c mice, and cross‐T responses these strains quantitated using interferon‐γ (IFN‐γ) Elispot. Peptides covering full‐length different detect epitope‐specific IFN‐γ + CD4 CD8 fluorescence‐activated sorting. Delta Omicron BA.1 found have broad cross‐reactivity, followed Beta strain. landscapes epitopes demonstrated at least 30 Alpha BA.5 can mediate escape its sublineages 19 out mutations, most which are new, few inherited ancient circulating concerns. immunity between prototype strain be attributed located N‐terminal domain (181–246 aa [amino acids], 271–318 aa) C‐terminal (1171–1273 protein. findings provide vivo evidence for optimizing manufacturing immunization strategies or future variants.

Language: Английский

Citations

1
COVID-19 vaccination affects short-term anti-coagulation levels in warfarin treatment DOI
Lihua Liu,

Yangzhao Zhou,

Tianyu Li

et al.

Journal of Thrombosis and Thrombolysis, Journal Year: 2024, Volume and Issue: 57(4), P. 730 - 738

Published: March 25, 2024

Language: Английский

Citations

1
Subunit protein-based vaccines DOI
Vasso Apostolopoulos, Vivek P. Chavda

Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 51 - 62

Published: Jan. 1, 2024

Language: Английский

Citations

1
Immunogenicity and safety of a recombinant COVID-19 vaccine (ZF2001) as heterologous booster after priming with inactivated vaccine in healthy children and adolescents aged 3-17 years: an open-labeled, single-arm clinical trial DOI Creative Commons
Tao Huang, Qianqian Hu, Zhou Xiang

et al.

BMC Infectious Diseases, Journal Year: 2024, Volume and Issue: 24(1)

Published: April 19, 2024

Considering that neutralizing antibody levels induced by two doses of the inactivated vaccine decreased over time and had fallen to low 6 months, homologous heterologous booster immunization programs have been implemented in adults China. The recombinant COVID-19 (ZF2001) after priming with healthy children adolescents has not reported. We performed an open-labeled, single-arm clinical trial evaluate safety immunogenicity ZF2001 among 240 population aged 3-17 years primary outcome was immunogenicity, including geometric mean titers (GMTs), ratios (GMRs) seroconversion rates SARS-CoV-2 antibodies against prototype Omicron BA.2 variant at 14 days vaccination booster. On day post-booster, a third dose provided substantial increase responses minors, overall occurrence rate adverse reactions all were mild or moderate. results showed high good profile adolescents, can elicit certain level Omicron.Trial registration NCT05895110 (Retrospectively registered, First posted ClinicalTrials.gov date: 08/06/2023).

Language: Английский

Citations

1